Skip to main content

clobazam (Tapclob®)

 

Status: Medicine does not meet criteria for AWMSG assessment

Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information.

Medicine details

Medicine name clobazam (Tapclob®)
Formulation 5 mg/5 ml and 10 mg/5 ml oral suspension
Reference number 2009
Indication

Short-term relief (2-4 weeks) only of anxiety that is severe, disabling or subjecting the individual to unacceptable distress, occurring alone or in association with insomnia or short term psychosomatic, organic or psychotic illness. The use of clobazam to treat short-term “mild” anxiety is inappropriate and unsuitable. Before treatment of anxiety states associated with emotional instability, it must first be determined whether the patient suffers from a depressive disorder requiring adjunctive or different treatment. Indeed, in patients with anxiety associated with depression, clobazam must be used only in conjunction with adequate concomitant treatment. Use of benzodiazepine (such as clobazam) alone, can precipitate suicide in such patients. In patients with schizophrenic or other psychotic illnesses, use of benzodiazepines is recommended only for adjunctive, i.e. not for primary treatment. Clobazam may be used as adjunctive therapy in epilepsy

Company Martindale Pharma
BNF chapter Central nervous system
Assessment type N/A
Status Medicine does not meet criteria for AWMSG assessment
Date of issue 24/05/2013
Follow AWTTC: